Targeted therapies for treatment of non-small cell lung cancer - Recent advances and future perspectives

International Journal of Cancer

Volumn 138, Issue 11, 2016, Pages 2549-2561

  Minguet, Joan ^a,b   Smith, Katherine H ^a   Bramlage, Peter ^a,b  

^a European Institute of Cancer Research (EICR)   (Spain)

^b INSTITUTE FOR PHARMACOLOGY AND PREVENTIVE MEDICINE   (Germany)

Author keywords

anaplastic lymphoma kinase; epidermal growth factor receptor; immune checkpoint inhibitors; mutations; targeted therapy; tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ALECTINIB; ATEZOLIZUMAB; BEVACIZUMAB; CERITINIB; CETUXIMAB; CREATINE KINASE; CRIZOTINIB; DACOMITINIB; DOCETAXEL; DURVALUMAB; ERLOTINIB; GANETESPIB; GEFITINIB; IPILIMUMAB; NERATINIB; NINTEDANIB; NIVOLUMAB; OSIMERTINIB; PEMBROLIZUMAB; PEMETREXED; PLACEBO; ROCILETINIB; SELUMETINIB; SORAFENIB; SUNITINIB; TIVANTINIB; VANDETANIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE REARRANGEMENT; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; MELANOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL LUNG CARCINOMA; VISUAL DISORDER; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84950341627     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29915     Document Type: Review

References (147)

1. World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worlwide in 2012. 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. (Accessed on March 2015).
2. Ettinger DS, Akerley W, Bepler G, et al., Non-small cell lung cancer. J Natl Compr Canc Netw 2010; 8: 740-801.
3. Klastersky J, Paesmans M., Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer 2001; 34: S95-101.
4. Soda M, Choi YL, Enomoto M, et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
5. Topalian SL, Weiner GJ, Pardoll DM., Cancer immunotherapy comes of age. J Clin Oncol 2011; 29: 4828-36.
6. Cagle PT, Allen TC., Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 2012; 136: 1482-91.
7. Sanford M, Scott LJ., Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 2009; 69: 2303-28.
8. Ranson M, Hammond LA, Ferry D, et al., ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50.
9. Herbst RS, Maddox AM, Rothenberg ML, et al., Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-25.
10. Baselga J, Rischin D, Ranson M, et al., Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-302.
11. Fukuoka M, Yano S, Giaccone G, et al., Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-46.
12. Kris MG, Natale RB, Herbst RS, et al., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003; 290: 2149-58.
13. Cohen MH, Williams GA, Sridhara R, et al., United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-8.
14. Rusch V, Baselga J, Cordon-Cardo C, et al., Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-85.
15. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
16. Paez JG, Janne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
17. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
18. Fukuoka M, Wu YL, Thongprasert S, et al., Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
19. Sekine I, Ichinose Y, Nishiwaki Y, et al., Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol 2009; 20: 1483-8.
20. Lee DH, Park K, Kim JH, et al., Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16: 1307-14.
21. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
22. Sequist LV, Martins RG, Spigel D, et al., First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
23. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8.
24. Inoue A, Kobayashi K, Maemondo M, et al., Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54-9.
25. Mitsudomi T, Morita S, Yatabe Y, et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
26. Thongprasert S, Duffield E, Saijo N, et al., Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011; 6: 1872-80.
27. Hidalgo M, Siu LL, Nemunaitis J, et al., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79.
28. Perez-Soler R, Chachoua A, Hammond LA, et al., Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
29. Shepherd FA, Rodrigues Pereira J, et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
30. Zhou C, Wu YL, Chen G, et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
31. Rosell R, Carcereny E, Gervais R, et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
32. Lee SM, Khan I, Upadhyay S, et al., First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012; 13: 1161-70.
33. Keedy VL, Temin S, Somerfield MR, et al., American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-7.
34. Carrera S, Buque A, Azkona E, et al., Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol 2014; 16: 339-50.
35. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73
36. Yu HA, Arcila ME, Rekhtman N, et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
37. Metro G, Crino L., Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 2012; 1: 5-13.
38. Stewart EL, Tan SZ, Liu G, et al., Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-A review. Transl Lung Cancer Res 2015; 4: 67-81.
39. Sharma SV, Bell DW, Settleman J, et al., Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-81.
40. Yun CH, Mengwasser KE, Toms AV, et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-5.
41. Baselga J., Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. J Clin Oncol 2006; 24: 2225-6.
42. Carter TA, Wodicka LM, Shah NP, et al., Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102: 11011-6.
43. Kwak EL, Sordella R, Bell DW, et al., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102: 7665-70.
44. Schwartz PA, Kuzmic P, Solowiej J, et al., Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci USA 2014; 111: 173-8.
45. Li D, Ambrogio L, Shimamura T, et al., BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27: 4702-11.
46. Eskens FA, Mom CH, Planting AS, et al., A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008; 98: 80-5.
47. Yap TA, Vidal L, Adam J, et al., Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28: 3965-72.
48. Miller VA, Hirsh V, Cadranel J, et al., Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13: 528-38.
49. Yang JC, Shih JY, Su WC, et al., Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13: 539-48.
50. Sequist LV, Yang JC, Yamamoto N, et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34.
51. Katakami N, Atagi S, Goto K, et al., LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013; 31: 3335-41.
52. Yang JC, Hirsh V, Schuler M, et al., Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3342-50.
53. Keating GM., Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs 2014; 74: 207-21.
54. Engelman JA, Zejnullahu K, Gale CM, et al., PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-32.
55. Gonzales AJ, Hook KE, Althaus IW, et al., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7: 1880-9.
56. Jänne PA, Boss DS, Camidge DR, et al., Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011; 17: 1131-9.
57. Takahashi T, Boku N, Murakami H, et al., Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012; 30: 2352-63.
58. Ramalingam SS, Blackhall F, Krzakowski M, et al., Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012; 30: 3337-44.
59. Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, et al., A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014; 120: 1145-54.
60. Ramalingam SS, Janne PA, Mok T, et al., Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 1369-78.
61. Ellis PM, Shepherd FA, Millward M, et al., Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol 2014; 15: 1379-88.
62. Wong KK, Fracasso PM, Bukowski RM, et al., A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009; 15: 2552-8.
63. Sequist LV, Besse B, Lynch TJ, et al., Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 3076-83.
64. Watanabe S, Minegishi Y, Yoshizawa H, et al., Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 2014; 9: 189-94.
65. Walter AO, Sjin RT, Haringsma HJ, et al., Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-15.
66. Tjin Tham Sjin R, Lee K, Walter AO, et al., In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther 2014; 13: 1468-79.
67. Sequist LV, Soria JC, Goldman JW, et al., Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015; 372: 1700-9.
68. Cortot AB, Repellin CE, Shimamura T, et al., Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013; 73: 834-43.
69. Lee Y, Wang Y, James M, et al., Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells. Mol Carcinog 2015 Jun 4. doi: 10.1002/mc.22342. [Epub ahead of print].
70. Cross DA, Ashton SE, Ghiorghiu S, et al., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046-61.
71. Jänne PA, Yang JC, Kim DW, et al., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-99.
72. Yang J, Kim D, Planchard D, et al., Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC). European Society for Medical Oncology; 2014; Madrid, Spain; 2014.
73. Butts CA, Bodkin D, Middleman EL, et al., Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007; 25: 5777-84.
74. Pennell NA, Mekhail T., Investigational agents in the management of non-small cell lung cancer. Curr Oncol Rep 2009; 11: 275-84.
75. Rosell R, Robinet G, Szczesna A, et al., Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008; 19: 362-9.
76. Pirker R, Pereira JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-31.
77. Pirker R, Pereira JR, von Pawel J, et al., EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13: 33-42.
78. Kim ES, Neubauer M, Cohn A, et al., Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013; 14: 1326-36.
79. Redman MW, Crowley JJ, Herbst RS, et al., Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012; 18: 4004-12.
80. Solomon B, Varella-Garcia M, Camidge DR., ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009; 4: 1450-4.
81. Gainor JF, Varghese AM, Ou SH, et al., ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013; 19: 4273-81.
82. Christensen JG, Zou HY, Arango ME, et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007; 6: 3314-22.
83. Kwak EL, Bang YJ, Camidge DR, et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
84. Camidge DR, Bang YJ, Kwak EL, et al., Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-9.
85. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-94.
86. Solomon BJ, Mok T, Kim DW, et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-77.
87. Blackhall F, Kim DW, Besse B, et al., Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol 2014; 9: 1625-33.
88. Malik SM, Maher VE, Bijwaard KE, et al., U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20: 2029-34.
89. Toyokawa G, Seto T., ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? Clin Lung Cancer 2014; 15: 313-9.
90. Katayama R, Shaw AT, Khan TM, et al., Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4: 120ra17.
91. Doebele RC, Pilling AB, Aisner DL, et al., Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472-82.
92. Li S, Qi X, Huang Y, et al., Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer 2015; 16: 86-91.
93. Friboulet L, Li N, Katayama R, et al., The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4: 662-73.
94. Shaw AT, Kim DW, Mehra R, et al., Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189-97.
95. Massarelli E, Papadimitrakopoulou V., Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer. Clin Cancer Res 2015; 21: 670-4.
96. Sakamoto H, Tsukaguchi T, Hiroshima S, et al., CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679-90.
97. Kodama T, Tsukaguchi T, Yoshida M, et al., Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014; 351: 215-21.
98. Seto T, Kiura K, Nishio M, et al., CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14: 590-8.
99. Gordon MS, Margolin K, Talpaz M, et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
100. Johnson DH, Fehrenbacher L, Novotny WF, et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
101. Sandler A, Gray R, Perry MC, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
102. Reck M, von Pawel J, Zatloukal P, et al., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
103. Reck M, von Pawel J, Zatloukal P, et al., Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
104. Majem M, Pallares C., An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol 2013; 15: 343-57.
105. Dhillon S., Nintedanib: a review of its use as second-line treatment in adults with advanced non-small cell lung cancer of adenocarcinoma histology. Target Oncol 2015; 10: 303-10.
106. Rolfo C, Raez LE, Bronte G, et al., BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013; 22: 1081-8.
107. Reck M, Kaiser R, Mellemgaard A, et al., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-55.
108. de Boer RH, Arrieta O, Yang CH, et al., Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-74.
109. Herbst RS, Sun Y, Eberhardt WE, et al., Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619-26.
110. Lee JS, Hirsh V, Park K, et al., Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114-21.
111. Scagliotti G, Novello S, von Pawel J, et al., Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-42.
112. Heist RS, Wang X, Hodgson L, et al., CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2014; 9: 214-21.
113. Drake CG, Jaffee E, Pardoll DM., Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
114. Keir ME, Butte MJ, Freeman GJ, et al., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
115. Topalian SL, Drake CG, Pardoll DM., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-12.
116. Korman AJ, Peggs KS, Allison JP., Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
117. Pardoll DM., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
118. Robert C, Soria JC, Eggermont AM., Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 2013; 49: 2968-71.
119. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
120. Brahmer JR, Drake CG, Wollner I, et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
121. Gettinger SN, Horn L, Gandhi L, et al., Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-12.
122. Rizvi NA, Mazieres J, Planchard D, et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-65.
123. Brahmer J, Reckamp KL, Baas P, et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
124. Patnaik A, Kang SP, Rasco D, et al., Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21: 4286-93.
125. Garon EB, Rizvi NA, Hui R, et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28.
126. Herbst RS, Soria JC, Kowanetz M, et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
127. Stewart R, Morrow M, Hammond SA, et al., Identification and pre-clinical characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 2015; 3: 1052-62.
128. Lynch TJ, Bondarenko I, Luft A, et al., Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30: 2046-54.
129. Feng Y, Thiagarajan PS, Ma PC., MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012; 7: 459-67.
130. Eathiraj S, Palma R, Volckova E, et al., Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011; 286: 20666-76.
131. Scagliotti G, von Pawel J, Novello S, et al., Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015; 33: 2667-74.
132. Camidge DR, Ou SH, Shapiro GI, et al., Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014; 32.
133. Paik PK, Drilon A, Fan PD, et al., Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discov 2015; 5: 842-9.
134. Bergethon K, Shaw AT, Ou SH, et al., ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-70.
135. Gainor JF, Shaw AT., Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013; 18: 865-75.
136. Shaw AT, Ou SH, Bang YJ, et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-71.
137. Mazieres J, Zalcman G, Crino L, et al., Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015; 33: 992-9.
138. Hainsworth JD, Cebotaru CL, Kanarev V, et al., A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010; 5: 1630-6.
139. Whitesell L, Lindquist SL., HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
140. Taipale M, Jarosz DF, Lindquist S., HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-28.
141. Socinski MA, Goldman J, El-Hariry I, et al., A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013; 19: 3068-77.
142. Ying W, Du Z, Sun L, et al., Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11: 475-84.
143. Smith DL, Acquaviva J, Sequeira M, et al., The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol 2015; 10: 235-45.
144. Kloth M, Buettner R., Changing histopathological diagnostics by genome-based tumor classification. Genes (Basel) 2014; 5: 444-59.
145. Bonanno L, Favaretto A, Rugge M, et al., Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011; 71: 2231-46.
146. Ang YL, Tan HL, Soo RA., Best practice in the treatment of advanced squamous cell lung cancer. Ther Adv Respir Dis, in press.
147. Kim HS, Mitsudomi T, Soo RA, et al., Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 2013; 80: 249-55.